By Maggie Fick and Bhanvi Satija LONDON, Feb 6 (Reuters) - Hims & Hers' gambit to sell a $49 compounded version of Novo ...

Pfizer made one thing clear this week: It's officially back in the obesity race.

Hims & Hers' gambit to sell a $49 compounded version of Novo Nordisk's Wegovy pill is rattling obesity shares, sparking ...

Doctors, patients and researchers are at the very beginning of understanding how the new class of obesity drugs interact with ...

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is ...

More than 50% of patients with overweight or obesity, A1c levels of 6.0%-6.4%, and a recent myocardial infarction progress to ...

Pfizer shares fell 3.3% Tuesday on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and costly bidding war ...

News and commentary from the endocrinology world ...

Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. Click here to read ...

The obesity-drug trade hit a speed bump. Still, there are reasons investors might want to sit tight. Novo Nordisk ...

A team of scientists has uncovered a critical mechanism that could pave the way for safer and more effective obesity ...